Literature DB >> 22502866

The poly(A)-binding protein nuclear 1 suppresses alternative cleavage and polyadenylation sites.

Mathias Jenal1, Ran Elkon, Fabricio Loayza-Puch, Gijs van Haaften, Uwe Kühn, Fiona M Menzies, Joachim A F Oude Vrielink, Arnold J Bos, Jarno Drost, Koos Rooijers, David C Rubinsztein, Reuven Agami.   

Abstract

Alternative cleavage and polyadenylation (APA) is emerging as an important layer of gene regulation. Factors controlling APA are largely unknown. We developed a reporter-based RNAi screen for APA and identified PABPN1 as a regulator of this process. Genome-wide analysis of APA in human cells showed that loss of PABPN1 resulted in extensive 3' untranslated region shortening. Messenger RNA transcription, stability analyses, and in vitro cleavage assays indicated enhanced usage of proximal cleavage sites (CSs) as the underlying mechanism. Using Cyclin D1 as a test case, we demonstrated that enhanced usage of proximal CSs compromises microRNA-mediated repression. Triplet-repeat expansion in PABPN1 (trePABPN1) causes autosomal-dominant oculopharyngeal muscular dystrophy (OPMD). The expression of trePABPN1 in both a mouse model of OPMD and human cells elicited broad induction of proximal CS usage, linked to binding to endogenous PABPN1 and its sequestration in nuclear aggregates. Our results elucidate a novel function for PABPN1 as a suppressor of APA.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22502866     DOI: 10.1016/j.cell.2012.03.022

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  175 in total

Review 1.  Translational control by changes in poly(A) tail length: recycling mRNAs.

Authors:  Laure Weill; Eulàlia Belloc; Felice-Alessio Bava; Raúl Méndez
Journal:  Nat Struct Mol Biol       Date:  2012-06-05       Impact factor: 15.369

2.  PABPN1 shuts down alternative poly(A) sites.

Authors:  Martine Simonelig
Journal:  Cell Res       Date:  2012-05-29       Impact factor: 25.617

Review 3.  The Untranslated Regions of mRNAs in Cancer.

Authors:  Samantha L Schuster; Andrew C Hsieh
Journal:  Trends Cancer       Date:  2019-03-22

4.  Distribution and dynamics of transcription-associated proteins during parvovirus infection.

Authors:  Teemu O Ihalainen; Sami F Willman; Einari A Niskanen; Outi Paloheimo; Hanna Smolander; Juha P Laurila; Minna U Kaikkonen; Maija Vihinen-Ranta
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

5.  SVD identifies transcript length distribution functions from DNA microarray data and reveals evolutionary forces globally affecting GBM metabolism.

Authors:  Nicolas M Bertagnolli; Justin A Drake; Jason M Tennessen; Orly Alter
Journal:  PLoS One       Date:  2013-11-25       Impact factor: 3.240

Review 6.  TGF-beta signaling in cancer: post-transcriptional regulation of EMT via hnRNP E1.

Authors:  Breege V Howley; Philip H Howe
Journal:  Cytokine       Date:  2018-02-01       Impact factor: 3.861

7.  U1 snRNP-mediated poly(A) site suppression: beneficial and deleterious for mRNA fate.

Authors:  Jörg Langemeier; Maximilian Radtke; Jens Bohne
Journal:  RNA Biol       Date:  2013-01-16       Impact factor: 4.652

Review 8.  RNA-binding proteins in neurodegeneration: Seq and you shall receive.

Authors:  Julia K Nussbacher; Ranjan Batra; Clotilde Lagier-Tourenne; Gene W Yeo
Journal:  Trends Neurosci       Date:  2015-03-09       Impact factor: 13.837

9.  Alternative Polyadenylation in Triple-Negative Breast Tumors Allows NRAS and c-JUN to Bypass PUMILIO Posttranscriptional Regulation.

Authors:  Wayne O Miles; Antonio Lembo; Angela Volorio; Elena Brachtel; Bin Tian; Dennis Sgroi; Paolo Provero; Nicholas Dyson
Journal:  Cancer Res       Date:  2016-10-10       Impact factor: 12.701

Review 10.  Faulty RNA splicing: consequences and therapeutic opportunities in brain and muscle disorders.

Authors:  Vittoria Pagliarini; Piergiorgio La Rosa; Claudio Sette
Journal:  Hum Genet       Date:  2017-04-22       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.